This page is provided for research and educational purposes only and does not provide medical advice, diagnosis, treatment recommendations, dosing instructions, or instructions for human use. Research findings should be interpreted within the population, model, formulation, route, outcomes, and study design reported by each cited source.
Thymosin Alpha-1 (10 mg Vial)
This information is for research and educational use only.
Quick Reference
What is Thymosin Alpha-1?
Research overview based on the cited scientific literature.
Goal: Support immune modulation and enhance host defense mechanisms[1][2].
Storage: Lyophilized refrigerated or frozen; reconstituted refrigerated; use within 7 days.
Storage Instructions
Proper storage preserves peptide quality.
Lyophilized: Store at 2–8 °C (35.6–46.4 °F) for short-term or −20 °C (−4 °F) for long-term; minimize moisture exposure[5].
Reconstituted: Refrigerate at 2–8 °C (35.6–46.4 °F); use within 7 days when using bacteriostatic water; avoid freeze–thaw.
Allow vials to reach room temperature before opening to reduce condensation uptake.
How is Thymosin Alpha-1 studied?
Thymosin Alpha-1 is a naturally occurring thymic peptide that modulates immune function through multiple pathways[1]. It enhances the maturation and differentiation of Tcells, augments dendritic cell function, and promotes the production of key cytokines including interferonα and interleukin2[2][6]. Clinical studies have demonstrated Tα1’s ability to enhance immune responses in immunocompromised individuals, including those with chronic hepatitis B and C infections[4]. Meta-analyses have also shown benefit in reducing mortality in moderate-to-critical COVID-19 patients[3].
What does the research report about Thymosin Alpha-1?
Observations from preclinical and clinical literature.
Supports enhanced Tcell function and overall immune competence[1][2].
Demonstrates an excellent safety profile; doses up to 1.6 mg twice weekly for 6–12 months have been well-tolerated[4][7].
Even at experimental doses up to 16 mg SC over 12 months, no significant Tα1specific toxicity has been observed[7].
Most common adverse effect is mild injectionsite irritation (redness or discomfort).
Important Note
This content is provided for scientific research and educational purposes only. It does not provide medical advice, diagnosis, treatment, dosing, or administration instructions. The compounds discussed may be investigational and are not presented as approved for human use.
What are the limitations of the research on Thymosin Alpha-1?
Evidence should be interpreted within the population, experimental model, formulation, route, outcome measures, and study design used in each cited source. Preclinical or early-stage findings do not establish clinical efficacy, safety, or approved human use. Where human evidence is available, results should not be generalized beyond the populations and conditions actually studied.
